{
    "events":
    [
        {
            "media":
            {
                "caption": "New Pfizer Results: Coronavirus Vaccine Is Safe and 95% Effective",
                "credit": "<a style=\"color:white;\" href=\"https://www.nytimes.com/2020/11/18/health/pfizer-covid-vaccine.html\" target=\"_blank\">Nytimes.com</a>",
                "url": "/doc/pfizer_trials/trial_timeline/nytimes_20201118.png"
            },
            "start_date":
            {
                "day": "18",
                "month": "11",
                "year": "2020"
            },
            "text":
            {
                "headline": "95% Efficacy via Press",
                "text": "<b>New Pfizer Results: Coronavirus Vaccine Is Safe and 95% Effective</b><p>The company said it planned to apply for emergency approval from the Food and Drug Administration \"within days.\"</p>"
            }
        },
        {
            "media":
            {
                "caption": "FDA Submission",
                "credit": "<a style=\"color:white;\" href=\"https://www.fda.gov/media/144416/download\" target=\"_blank\">Fda.gov</a>",
                "url": "/doc/pfizer_trials/trial_timeline/fda_20201120.png"
            },
            "start_date":
            {
                "day": "20",
                "month": "11",
                "year": "2020"
            },
            "text":
            {
                "headline": "FDA Submission",
                "text": "<b>Emergency Use Authorization (EUA) for an Unapproved Product Review Memorandum</b><p>On November 20, 2020, the Sponsor (Pfizer, on behalf of Pfizer and BioNTech) submitted an Emergency Use Authorization (EUA) request to FDA for an investigational COVID-19 vaccine (BNT162b2) intended to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).</p>"
            }
        },
        {
            "media":
            {
                "caption": "FDA Point of Submission",
                "credit": "<a style=\"color:white;\" href=\"https://www.fda.gov/media/144245/download\" target=\"_blank\">Fda.gov</a>",
                "url": "/doc/pfizer_trials/trial_timeline/fda_144245.png"
            },
            "start_date":
            {
                "day": "10",
                "month": "12",
                "year": "2020"
            },
            "text":
            {
                "headline": "FDA Point of Submission",
                "text": "<b>FDA Briefing Document - Pfizer-BioNTech COVID-19 Vaccine</b><p>The Vaccines and Related Biological Products Advisory Committee will convene on December 10, 2020, to discuss and provide recommendations on whether:<ul><li>based on the totality of scientific evidence available, it is reasonable to believe that the Pfizer-BioNTech COVID-19 Vaccine may be effective in preventing COVID-19 in individuals 16 years of age and older, and</li><li>the known and potential benefits of the Pfizer-BioNTech COVID-19 Vaccine outweigh its known and potential risks for use in individuals 16 years of age and older.</li></p>"
            }
        },
        {
            "media":
            {
                "caption": "FDA EUA Granted",
                "credit": "<a style=\"color:white;\" href=\"https://www.cdc.gov/mmwr/volumes/69/wr/mm6950e2.htm\" target=\"_blank\">Cdc.gov</a>",
                "url": "/doc/pfizer_trials/trial_timeline/cdc_20201211.png"
            },
            "start_date":
            {
                "day": "11",
                "month": "12",
                "year": "2020"
            },
            "text":
            {
                "headline": "FDA EUA Granted",
                "text": "<b>The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020</b><p>On December 11, 2020, the Food and Drug Administration issued an Emergency Use Authorization for the Pfizer-BioNTech COVID-19 vaccine.</p>"
            }
        },
        {
            "media":
            {
                "caption": "Safety/Efficacy Study",
                "credit": "<a style=\"color:white;\" href=\"https://www.nejm.org/doi/full/10.1056/nejmoa2034577\" target=\"_blank\">Nejm.org</a>",
                "url": "/doc/pfizer_trials/trial_timeline/nejm_20201210.png"
            },
            "start_date":
            {
                "day": "31",
                "month": "12",
                "year": "2020"
            },
            "text":
            {
                "headline": "Safety/Efficacy Study",
                "text": "<b>Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine</b><p>There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6).</p>"
            }
        },
        {
            "media":
            {
                "caption": "PHMPT's FOI",
                "credit": "<a style=\"color:white;\" href=\"https://phmpt.org/\" target=\"_blank\">Phmpt.org</a>",
                "url": "/doc/pfizer_trials/trial_timeline/phmpt_home.png"
            },
            "start_date":
            {
                "day": "27",
                "month": "08",
                "year": "2021"
            },
            "text":
            {
                "headline": "PHMPT's FOI",
                "text": "<b>Public Health and Medical Professionals for Transparency</b><p>Four days after the Pfizer vaccine was approved for ages 16+, we submitted a Freedom of Information Act Request to the FDA for all of the data within Pfizer's COVID-19 vaccine biological product file.</p>"
            }
        },
        {
            "media":
            {
                "caption": "PHMPT sues the FDA",
                "credit": "<a style=\"color:white;\" href=\"https://phmpt.org/\" target=\"_blank\">Phmpt.org</a>",
                "url": "/doc/pfizer_trials/trial_timeline/phmpt_lawsuit.png"
            },
            "start_date":
            {
                "day": "16",
                "month": "09",
                "year": "2021"
            },
            "text":
            {
                "headline": "PHMPT sues the FDA",
                "text": "<b>COMPLAINT FOR DECLARATORY AND INJUNCTIVE RELIEF</b><p>On September 9, 2021, the FDA denied PHMPT's request for expedited processing on the basis that PHMPT did \"not demonstrate[] a compelling need that involves an imminent threat to the life or physical safety of an individual\" or \"that there exists an urgency to inform the public concerning actual or alleged Federal Government activity.\" PHMPT brings this action to challenge the FDA's determination and seeks an order compelling the FDA to produce responsive records on an expedited basis. </p>"
            }
        },
        {
            "media":
            {
                "caption": "PHMPT docs release",
                "credit": "<a style=\"color:white;\" href=\"https://phmpt.org/pfizers-documents/\" target=\"_blank\">Phmpt.org</a>",
                "url": "/doc/pfizer_trials/trial_timeline/phmpt_release.png"
            },
            "start_date":
            {
                "day": "17",
                "month": "11",
                "year": "2021"
            },
            "text":
            {
                "headline": "PHMPT docs release",
                "text": "<b>Pfizer's Documents</b><p>Documents with a large file size are provided in a .zip file and will need to be uncompressed after download.</p>"
            }
        }
    ],
    "title":
    {
        "media":
        {
            "caption": "Pfizer/BioNTech C4591001 Trial Timeline",
            "credit": "Pexels",
            "url": "/doc/pfizer_trials/trial_timeline/cover.png"
        },
        "text":
        {
            "headline": "<b>Pfizer/BioNTech C4591001 Trial</b>",
            "text": "<p>This timeline features the important dates of the Pfizer/BioNTech C4591001 Trial, which led to the EUA Approval and assumed efficacy.</p>"
        }
    }
}